|
29/07/2022 |
Nasalferon in ARI |
CIGB |
Registered |
|
12/11/2021 |
Nasalferon in COVID-19 |
CIGB |
Registered |
|
2012-10-12 |
NASVAC Phase II Trial in patients with Chronic Hepatitis B Virus infection |
CIGB |
Registered |
|
2011-05-16 |
NASVAC therapeutic vaccine study |
CIGB |
Registered |
|
2013-06-10 |
NeuroEPO in healthy volunteers. |
CIMAB |
Registered |
|
20/09/2022 |
NeuroEPO in mild-moderate Alzheimer's disease |
CIM |
Registered |
|
22/09/2022 |
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant |
CIM |
Registered |
|
01/02/2017 |
NeuroEPO in patients with Mild-Moderate Alzheimer's disease |
CIM |
Registered |
|
01/02/2017 |
NeuroEPO in patients with Parkinson disease stage II-III |
CIM |
Registered |
|
02/08/2018 |
NeuroEPO in stroke |
CIM |
Registered |
|
02/11/2014 |
NeuroEPO – Type 2 Spinocerebellar Ataxia Phase I-II |
CIMAB |
Registered |
|
19/11/2020 |
NeuroEPO-Ataxia-Adults-Phase III |
CIM |
Registered outdated |
|
11/09/2014 |
NeuroEPO-Stroke. Phase I-II |
CIMAB |
Registered |
|
2011-04-30 |
NEUVITAL V Study |
CIGB |
Registered |
|
12/10/2016 |
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer |
CIM |
Registered |
|
07/12/2016 |
NGcGM3/VSSP in Metastatic melanoma |
CIM |
Registered |
|
28/11/2016 |
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer |
CIM |
Registered |
|
07/12/2016 |
NGcGM3/VSSP in small cell lung cancer |
CIM |
Registered outdated |
|
2010-12-17 |
NGcGM3/VSSP/Montanide ISA 51 vaccine for breast cancer IIa, IIb and IIIa surgically treated with positive ganglia and disease-free, Phase IIb/III. |
CIM |
Registered |
|
2010-12-17 |
NGcGM3/VSSP/Montanide ISA 51 vaccine in metastatic breast cancer. Phase II |
CIM |
Registered |
